Ads
related to: ca15 3 biomarker- MET Biomarker Testing
Explore MET Biomarker Testing
Methodologies & Detection Methods
- Poor Prognosis In NSCLC
Learn about MET Biomarkers
and Poorer Prognosis in NSCLC
- MET Aberrations In NSCLC
Review the Current & Emerging MET
Biomarkers Prevalent in NSCLC
- MET Biomarker Prevalence
Explore MET Biomarkers
Prevalent in NSCLC
- MET Biomarker Testing
Search results
Results From The WOW.Com Content Network
CA 15-3, for Carcinoma Antigen 15-3, is a tumor marker for many types of cancer, most notably breast cancer. [1] [2] [3]It is derived from MUC1. [4] CA 15-3 and associated CA 27-29 are different epitopes on the same protein antigen product of the breast cancer-associated MUC1 gene.
A tumor marker is a biomarker that can be used to indicate the presence of cancer or the behavior of cancers (measure progression or response to therapy). They can be found in bodily fluids or tissue. Markers can help with assessing prognosis, surveilling patients after surgical removal of tumors, and even predicting drug-response and monitor ...
CA 27.29 (aka BR 27.29) and CA 15-3 measure different epitopes of the same protein antigen product of the MUC1 gene seen in breast cancer. CA 27.29 has enhanced sensitivity and specificity compared to CA 15-3 and is elevated in 30% of patients with low-stage disease and 60 to 70% of patients with advanced-stage breast cancer.
Biomarkers found in blood, urine, or body tissues that can be introduced or elevated by the presence of one or more types of cancer. Pages in category "Tumor markers" The following 45 pages are in this category, out of 45 total.
Language links are at the top of the page across from the title.
3 blood biomarkers may be key to predicting cardiovascular risk. For this study, researchers analyzed data from the Women’s Health Study (WHS), funded by the National Institutes of Health (NIH ...